drugset
drugset / Trial / NCT05202561

A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors

NCT05202561 ↗

Phase 1 Unknown 10 enrolled The First Affiliated Hospital of Bengbu Medical University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, clinical pharmacology study to evaluate the safety of RNA tumor vaccine injection alone/in combination with PD-1 inhibitor in the treatment of advanced solid tumors with KRAS mutation. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, pharmacokinetics and of RNA tumor vaccine.

Timeline

Start
2022-03-10
Primary completion
2023-01-19
Completion
2024-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Navuliumab Unknown 3 mg/kg Intravenous
Subject RNA tumor vaccine Vaccine 600 ng Intramuscular

Indications

neoplasm